Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin

Cancer

Volumn 83, Issue 7, 1998, Pages 1344-1354

  Bow, Eric J ^a,c   Gallant, Gilles ^b   Williams, Gaynor J ^a   Woloschuk, Donna ^a   Shore, Tsiporah B ^a   Rubinger, Morel ^a   Schacter, Brent A ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b BRISTOL MYERS SQUIBB   (United States)

^c HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Acute myeloid leukemia; Mucosal toxicity; Non cytarabine based induction regimens

Indexed keywords

CARBOPLATIN; CYTARABINE; ETOPOSIDE; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; TREATMENT OUTCOME; VOMITING;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; DRUG TOLERANCE; ETOPOSIDE; FEMALE; HUMANS; IDARUBICIN; INTESTINAL MUCOSA; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PILOT PROJECTS; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; XYLOSE;

EID: 0032188851     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19981001)83:7<1344::AID-CNCR11>3.0.CO;2-4     Document Type: Article

References (38)

1. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994;331: 896-903.
2. Bishop JF, Lowenthal RM, Joshua D, Matthews JP, Todd D, Cobcroft R, et al. Etoposide in acute nonlymphocytic leukemia. Blood 1990;75:27-32.
3. Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991;77:1666-74.
4. Vogler WR, Velez-Garcia E, Weiner RS, Flaum MA, Bartolucci AA, Omura GA, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study. J Clin Oncol 1992;10:1103-11.
5. Wiernik PH, Banks PLC, Case DC Jr., Zalmen A, Arlin A, Periman PO, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992;79:313-9.
6. Bow EJ, Kilpatrick MG, Scott BA, Clinch J, Cheang MS. Acute myeloid leukemia in Manitoba: the consequences of standard "7 + 3" remission-induction therapy followed by highdose cytarabine post-remission consolidation for myelosuppression, infectious morbidity and outcome. Cancer 1994; 74:52-60.
7. Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, et al. A randomized investigation of highdose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1996;88:2841-51.
8. Dillman RO, Davis RB, Green MR, Weiss RB, Gottlieb AJ, Caplan S, et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood 1991;78:2520-6.
9. Phillips GL, Reece DE, Shepherd JD, Barnett MJ, Brown DA, Frei-Lahr DA, et al. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood 1991; 77:1429-35.
10. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996;87:1710-7.
11. Bochud P-Y, Calandra T, Franciola P. Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med 1994;97:256-64.
12. Bow EJ, Loewen R, Cheang MS, Schacter B. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis 1995;21:361-9.
13. Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM, et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992;79:1924-30.
14. Ho AD, Lipp T, Ehninger G, Illiger H-J, Meyer P, Freund M, et al. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia: an active and well tolerated regimen. J Clin Oncol 1988;6:213-7.
15. Rowe JM, Andersen JW, Mazza JJ, Hines JD, Bennett JM, Cassileth PA, et al. Treatment of relapsed and refractory AML with mitoxantrone and etoposide: a study of the Eastern Cooperative Oncology Group. Haematol Blood Transfus 1994:35:235-8.
16. Knauf WU, Berdel WE, Ho AD, Kreuser ED, Thiel E. Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia. Leuk Lymphoma 1994;12:421-5.
17. Bow EJ, Sutherland JA, Kilpatrick MG, Williams GJ, Clinch JJ, Shore TB, et al. Therapy of untreated acute myeloid leukemia in the elderly: remission induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. J Clin Oncol 1996;14:1345-52.
18. Martinez JA, Martin G, Sanz F, Sempere A, Jarque I, de la Rubia J, et al. A phase II clinical trial of carboplatin infusion in high-risk acute nonlymphocytic leukemia. J Clin Oncol 1991;9:39-43.
19. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnic HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:620-5.
20. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990;8: 813-9.
21. Mitelman F, editor. ISCN (1991). Cancer cytogenetics. Supplement to An International System for Human Cytogenetic Nomenclature. Basel; Karger, 1991.
22. Arthur DC, Berger R, Golumb HM, Swansbury GJ, Reeves BR, Alimena G, et al. The clinical significance of karyotype in acute myelogenous leukemia. Cancer Genet Cytogenet 1989; 40:203-16.
23. Swansbury GJ, Lawler SD, Alimena G, Arthur D, Berger R, Van Den Berghe H, et al. Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer Genet Cytogenet 1994;73:1-7.
24. Ferrant A, Labopin M, Frassoni F, Prentice HG, Cahn JY, Biaise D, et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Blood 1997;90:2931-8.
25. Bow EJ, Rayner E, Louie TJ. Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. Am J Med 1988;84:847-54.
26. Hughes NT, Armstrong D, Bodey GD, Feld R, Mandell GL, Meyers JD, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161:381-96.
27. Kaplan ER, Meier R. Non-parametric estimation from incompatible observations. J Am Stat Assoc 1958;53:457-81.
28. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-202.
29. Bow EJ, Patterson D, Gallant G, Loewen R, Shore T, Rubinger M, et al. Non-cytarabine-based remission-induction therapy for acute myeloid leukemia [Abstract No. 650]. Can J Infect Dis 1995;6(Suppl C):289C.
30. Del Poeta G, Stasi R, Aronica G, Venditti A, Cox MC, Bruno A, et al. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood 1996;87:1997-2004.
31. Marosi C, Köller U, Koler-Weber E, Schwarzinger I, Schneider B, Jäger U, et al. Prognostic impact of karyotype and immunologic phenotype in 125 adult patients with de novo AML. Cancer Genet Cytogenet 1992;61:14-25.
32. Stasi R, Del Poeta G, Masi M, Tribalto M, Venditti A, Papa G, et al. Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia. Cancer Genet Cytogenet 1993;67:28-34.
33. Fenaux P, Preudhomme C, Lai JL, Morel P, Beuscart R, Bauters F. Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases. Br J Haematol 1989;73:61-7.
34. Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 1995;332:1678-83.
35. Schiffer CA, Lee EJ, Tomiyasu T, Wiernik PH, Testa JR. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 1989; 73:263-70.
36. Berman E, Wiernik P, Vogler R, Velez-Garcia E, Bartolucci A, Whaley FS. Long term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia. Cancer 1997;80:2181-5.
37. Bloomfield CD, Lawrence D, Arthur DC, Berg DT, Schiffer CA, Mayer RJ. Curative impact of intensification with highdose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group [Abstract No. 431]. Blood 1994; 84(Suppl 1):111a.
38. Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission-induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 1997;90:4710-18.